- About CURE
Integrated Molecular Technologies Core (IMTC)
The overarching objective of the Integrated Molecular Technologies (IMT) Core is to promote and facilitate basic and translational GI research by providing CURE: DDRC investigators with access to state-of-the-art molecular technologies, including: 1) expertise, equipment and services for systems biology and high-throughput screening analyses; 2) expertise and viral vector cloning and production services to genetically engineer mammalian cell lines and primary cells for expression or inhibition of proteins and miRNAs both in vitro and in vivo.
The IMT Core, a merger of the former Vector Core and the Systems Biomedicine Center, represents an integrated unit intended to maximize efficiency and ease of utilization of molecular services by providing CURE: DDRCC investigators with access to state-of-the-art molecular technologies that enable efficient gene transfer, protein expression, and functional analysis in mammalian cells in culture and in vivo, as well as to perform protein analyses, genomic profiling, cellular phenotyping and high-throughput molecular screening. These technologies will assist CURE: DDRC investigators in their research efforts to understand the functional significance of specific genes and proteins during normal development and organogenesis in the gastrointestinal tract and to determine and answer fundamental questions on the functional significance of specific candidates genes and proteins to the pathogenesis or amelioration of digestive diseases, and to identify and validate novel therapeutic targets for conventional and experimental therapies.
The IMTC services include (but are not limited to): (1) consultation and troubleshooting in techniques for efficient gene delivery, as well as cloning and functional protein expression in mammalian cells in vitro and in vivo, (2) consultation and to perform customized gene expression profiling, cytological phenotype profiling, and high-throughput molecular screening studies by utilizing high-throughput and highly automated robotic systems. The Integrated Molecular Technologies Core (IMTC) is therefore intended to serve as a comprehensive resource that will provide access to state-of-the-art molecular tools and thereby aims to facilitate the research activities of CURE: DDRCC investigators.
Please contact Dr. Emmanuelle Faure-Kumar for any information regarding these different services.
Cloning , Retroviral vectors, Lentiviral vectors, Adenoviral vectors, and AAV
Assisting with the writing of IBC protocols
High-Throughput Molecular Profiling Platforms:
The Nanostring system can examine the expression levels of up to 800 genes or 750 microRNAs in the same sample in ~6 hr.
Luminex FlexMap3D system (BioRad) is available for high-throughput cytokine/chemokine and phosphoproteomic analyses, and can examine 96 samples simultaneously. BioRad Bio-Plex 3D with a Suspension Array System and Bio-Plex Pro II Wash Station is available for processing of xMAP assays which can be built on either magnetic beads or non-magnetic beads.
Drug Discovery Platforms: Biomek FX and NX automated workstation equipped with a robotic transport system (Beckman-Coulter) and EnVision multilabel plate reader (PerkinElmer) is available for high-throughput molecular screening studies to identify novel therapeutic candidates. More than 100,000 chemical compounds are available for high-throughput chemical screening on this platform.
Cellular Modeling Platform: The xCELLigence system (Roche Applied Science) is available for monitoring of cellular events in real time without the need for incorporation of labels, and can be used to quantitate cell number
Please note that the Vector Core has been integrated into the Integrated Molecular Technologies Core (IMTC). Please contact Emmanuelle Faure at the contact information below for information regarding the services.
- Retroviral vectors, Lentiviral vectors, Adenoviral vectors
Enrique Rozengurt, DVM, PhD
Acting Core Director
Dimitrios Iliopoulos, PhD
Emmanuelle Faure-Kumar, PhD